Global Selective Cox-2 Inhibitors Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Selective Cox-2 Inhibitors Market Overview

• 1.1 Product Overview and Scope of Selective Cox-2 Inhibitors
• 1.2 Classification of Selective Cox-2 Inhibitors by Types
  • 1.2.1 Global Selective Cox-2 Inhibitors Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global Selective Cox-2 Inhibitors Revenue Market Share by Types in 2018
  • 1.2.3 Meloxicam
  • 1.2.4 Celecoxib
  • 1.2.5 Etoricoxib
  • 1.2.6 Imrecoxib
  • 1.2.7 Etodolac
  • 1.2.8 Parecoxib
  • 1.2.9 Other
• 1.3 Global Selective Cox-2 Inhibitors Market by Application
  • 1.3.1 Global Selective Cox-2 Inhibitors Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Rheumatoid Arthritis
  • 1.3.3 Osteoarthritis
  • 1.3.4 Spondylosis Chronica Ankylopoietica
  • 1.3.5 Other
• 1.4 Global Selective Cox-2 Inhibitors Market by Regions
  • 1.4.1 Global Selective Cox-2 Inhibitors Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) Selective Cox-2 Inhibitors Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Selective Cox-2 Inhibitors Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Selective Cox-2 Inhibitors Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Selective Cox-2 Inhibitors Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Selective Cox-2 Inhibitors Status and Prospect (2014-2024)
• 1.5 Global Market Size of Selective Cox-2 Inhibitors (2014-2024)

2 Manufacturers Profiles

• 2.1 Boehringer-Ingelheim
  • 2.1.1 Business Overview
  • 2.1.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 TerSera Therapeutics
  • 2.2.1 Business Overview
  • 2.2.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 Iroko Pharmaceuticals
  • 2.3.1 Business Overview
  • 2.3.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 Apotex
  • 2.4.1 Business Overview
  • 2.4.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 Apotex Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Yung Shin Pharmaceutical
  • 2.5.1 Business Overview
  • 2.5.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 Breckenridge Pharmaceutical
  • 2.6.1 Business Overview
  • 2.6.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 Meda Pharmaceuticals
  • 2.7.1 Business Overview
  • 2.7.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Cipla
  • 2.8.1 Business Overview
  • 2.8.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Cipla Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Glenmark Pharmaceuticals
  • 2.9.1 Business Overview
  • 2.9.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.10 Teva
  • 2.10.1 Business Overview
  • 2.10.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.10.2.1 Product A
    • 2.10.2.2 Product B
  • 2.10.3 Teva Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.11 PuraCap Pharmaceutical
  • 2.11.1 Business Overview
  • 2.11.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.11.2.1 Product A
    • 2.11.2.2 Product B
  • 2.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.12 Almirall Limited
  • 2.12.1 Business Overview
  • 2.12.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.12.2.1 Product A
    • 2.12.2.2 Product B
  • 2.12.3 Almirall Limited Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.13 Lupin Pharmaceuticals
  • 2.13.1 Business Overview
  • 2.13.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.13.2.1 Product A
    • 2.13.2.2 Product B
  • 2.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.14 Aurobindo Pharma
  • 2.14.1 Business Overview
  • 2.14.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.14.2.1 Product A
    • 2.14.2.2 Product B
  • 2.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.15 Pfizer
  • 2.15.1 Business Overview
  • 2.15.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.15.2.1 Product A
    • 2.15.2.2 Product B
  • 2.15.3 Pfizer Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.16 Mylan
  • 2.16.1 Business Overview
  • 2.16.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.16.2.1 Product A
    • 2.16.2.2 Product B
  • 2.16.3 Mylan Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.17 Shire Pharmaceuticals
  • 2.17.1 Business Overview
  • 2.17.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.17.2.1 Product A
    • 2.17.2.2 Product B
  • 2.17.3 Shire Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.18 Bayer
  • 2.18.1 Business Overview
  • 2.18.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.18.2.1 Product A
    • 2.18.2.2 Product B
  • 2.18.3 Bayer Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.19 Novacap
  • 2.19.1 Business Overview
  • 2.19.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.19.2.1 Product A
    • 2.19.2.2 Product B
  • 2.19.3 Novacap Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.20 Abbott
  • 2.20.1 Business Overview
  • 2.20.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.20.2.1 Product A
    • 2.20.2.2 Product B
  • 2.20.3 Abbott Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.21 Geri-Care
  • 2.21.1 Business Overview
  • 2.2.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.21.2.1 Product A
    • 2.21.2.2 Product B
  • 2.21.3 Geri-Care Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.22 Perrigo
  • 2.22.1 Business Overview
  • 2.22.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.22.2.1 Product A
    • 2.22.2.2 Product B
  • 2.22.3 Perrigo Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.23 Kopran
  • 2.23.1 Business Overview
  • 2.23.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.23.2.1 Product A
    • 2.23.2.2 Product B
  • 2.23.3 Kopran Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.24 Merck
  • 2.24.1 Business Overview
  • 2.24.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.24.2.1 Product A
    • 2.24.2.2 Product B
  • 2.24.3 Merck Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.25 Hengrui pharmaceutical
  • 2.25.1 Business Overview
  • 2.25.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.25.2.1 Product A
    • 2.25.2.2 Product B
  • 2.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.26 Kelun Group
  • 2.26.1 Business Overview
  • 2.26.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.26.2.1 Product A
    • 2.26.2.2 Product B
  • 2.26.3 Kelun Group Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.27 Qilu Pharmaceutical
  • 2.27.1 Business Overview
  • 2.27.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.27.2.1 Product A
    • 2.27.2.2 Product B
  • 2.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)
• 2.28 Taro Pharmaceuticals
  • 2.28.1 Business Overview
  • 2.28.2 Selective Cox-2 Inhibitors Type and Applications
    • 2.28.2.1 Product A
    • 2.28.2.2 Product B
  • 2.28.3 Taro Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2017-2018)

3 Global Selective Cox-2 Inhibitors Market Competition, by Players

• 3.1 Global Selective Cox-2 Inhibitors Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Selective Cox-2 Inhibitors Players Market Share
  • 3.2.2 Top 10 Selective Cox-2 Inhibitors Players Market Share
• 3.3 Market Competition Trend

4 Global Selective Cox-2 Inhibitors Market Size by Regions

• 4.1 Global Selective Cox-2 Inhibitors Revenue and Market Share by Regions
• 4.2 North America Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 4.3 Europe Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 4.5 South America Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)

5 North America Selective Cox-2 Inhibitors Revenue by Countries

• 5.1 North America Selective Cox-2 Inhibitors Revenue by Countries (2014-2019)
• 5.2 USA Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 5.3 Canada Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 5.4 Mexico Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)

6 Europe Selective Cox-2 Inhibitors Revenue by Countries

• 6.1 Europe Selective Cox-2 Inhibitors Revenue by Countries (2014-2019)
• 6.2 Germany Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 6.3 UK Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 6.4 France Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 6.5 Russia Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 6.6 Italy Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Selective Cox-2 Inhibitors Revenue by Countries

• 7.1 Asia-Pacific Selective Cox-2 Inhibitors Revenue by Countries (2014-2019)
• 7.2 China Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 7.3 Japan Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 7.4 Korea Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 7.5 India Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)

8 South America Selective Cox-2 Inhibitors Revenue by Countries

• 8.1 South America Selective Cox-2 Inhibitors Revenue by Countries (2014-2019)
• 8.2 Brazil Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 8.3 Argentina Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 8.4 Colombia Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Selective Cox-2 Inhibitors by Countries

• 9.1 Middle East and Africa Selective Cox-2 Inhibitors Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 9.3 UAE Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 9.4 Egypt Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)
• 9.6 South Africa Selective Cox-2 Inhibitors Revenue and Growth Rate (2014-2019)

10 Global Selective Cox-2 Inhibitors Market Segment by Type

• 10.1 Global Selective Cox-2 Inhibitors Revenue and Market Share by Type (2014-2019)
• 10.2 Global Selective Cox-2 Inhibitors Market Forecast by Type (2019-2024)
• 10.3 Meloxicam Revenue Growth Rate (2014-2024)
• 10.4 Celecoxib Revenue Growth Rate (2014-2024)
• 10.5 Etoricoxib Revenue Growth Rate (2014-2024)
• 10.6 Imrecoxib Revenue Growth Rate (2014-2024)
• 10.7 Etodolac Revenue Growth Rate (2014-2024)
• 10.8 Parecoxib Revenue Growth Rate (2014-2024)
• 10.9 Other Revenue Growth Rate (2014-2024)

11 Global Selective Cox-2 Inhibitors Market Segment by Application

• 11.1 Global Selective Cox-2 Inhibitors Revenue Market Share by Application (2014-2019)
• 11.2 Selective Cox-2 Inhibitors Market Forecast by Application (2019-2024)
• 11.3 Rheumatoid Arthritis Revenue Growth (2014-2019)
• 11.4 Osteoarthritis Revenue Growth (2014-2019)
• 11.5 Spondylosis Chronica Ankylopoietica Revenue Growth (2014-2019)
• 11.6 Other Revenue Growth (2014-2019)

12 Global Selective Cox-2 Inhibitors Market Size Forecast (2019-2024)

• 12.1 Global Selective Cox-2 Inhibitors Market Size Forecast (2019-2024)
• 12.2 Global Selective Cox-2 Inhibitors Market Forecast by Regions (2019-2024)
• 12.3 North America Selective Cox-2 Inhibitors Revenue Market Forecast (2019-2024)
• 12.4 Europe Selective Cox-2 Inhibitors Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific Selective Cox-2 Inhibitors Revenue Market Forecast (2019-2024)
• 12.6 South America Selective Cox-2 Inhibitors Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa Selective Cox-2 Inhibitors Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology